The prevalence of various genetic mutations in NSCLC is described, such as driver mutations in KRAS and epidermal growth factor receptor (EGFR) which occur frequently and can influence therapeutic strategies (Zhu et al. 2017). Here, EGFR is linked to non-small cell lung carcinoma.